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P-2
Some practical considerations in the design of multi-arm multi-
stage designs
Jerome Wulff, Nikolaos Demiris
Cambridge Clinical Trial Unit, Cambridge, United Kingdom
Trials 2019, 20(Suppl 1):P-2
Introduction: In the design of cancer clinical trials, one is often con-
cerned with a number of options in the event that several treatments
are of interest.
Methods: We explore in this work the distinct possibilities when four
treatments are available, one acting as control and three as poten-
tially efficacious alternatives. This design may be embedded within
the context of multi-arm multi-stage (MAMS) trials where one may
select a two- or three-stage design.
Potential Results: We explore the application of such designs, in-
cluding trade-offs between potential gains in the number of pa-
tients with additional stages contrasted with patients “lost” due
to practical considerations such as patients randomised in
dropped arms while waiting for interim analyses and inspection
by an Independent Data and Safety Committee. In addition, in
cancer studies one may focus on the primary end-point using a
time-to-event analysis or a binary outcome by looking at the
probability of (potentially progression-free) survival at a specific,
clinically meaningful, time point. The effect of such choices is ex-
tensively investigated.
Potential Relevance & Impact: We conclude with a discussion of the
available software for MAMS designs and their advantages and dis-
advantages in terms of accuracy.
P-3
The UK plasma based Molecular profiling of Advanced breast cancer
to inform Therapeutic CHoices (plasmaMATCH) Trial: A multiple
parallel-cohort, phase IIa platform trial aiming to provide proof of
principle efficacy for designated targeted therapies in patient
subgroups identified through ctDNA screening (CRUK/15/010)
Sarah Kernaghan1, Laura Moretti1, Lucy Kilburn1, Katie Wilkinson1, Claire
Snowdon1, James Morden1, Iain Macpherson2, Andrew Wardley3,
Rebecca Roylance4, Richard Baird5, Alistair Ring6, Nicholas Turner7,
Judith M Bliss1, on behalf of the plasmaMATCH Trial Management
Group
1Clinical Trials and Statistics Unit at The Institute of Cancer Research
(ICR-CTSU), United Kingdom; 2The Beatson West of Scotland Cancer
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Institute of Cancer Research and The Royal Marsden NHS Foundation
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Trials 2019, 20(Suppl 1):P-3
Introduction: plasmaMATCH is a novel platform trial which assesses
the potential of circulating tumour DNA (ctDNA) screening to dir-
ect targeted therapies in advanced breast cancer (ABC) patients.
The trial recruited ahead of target and will report initial results
within 3years of first patient first visit demonstrating efficiency of
this design.
Methods: plasmaMATCH is an open-label, multi-centre phase IIa plat-
form trial, consisting of a ctDNA screening component and five paral-
lel treatment cohorts. Patients with an actionable mutation identified
at ctDNA screening are invited to enter Cohorts A-D to receive a tar-
geted treatment matched to the mutation identified (A: ESR1–ex-
tended-dose fulvestrant; B: HER2–neratinib+/-fulvestrant; C&D: AKT1
(or PTEN for Cohort D) –AZD5363+/-fulvestrant). Cohort E was added
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Introduction: Despite an ageing population and rising prevalence of
conditions associated with cognitive impairments, adults who lack
capacity to consent are under-represented in research. Trials involv-
ing adults who lack capacity raise a number of ethical and practical
challenges. Participants who are unable to consent require a family
member to act as a proxy decision-maker, however, families can ex-
perience an emotional and decisional burden as a result. Despite nu-
merous innovations to improve informed consent processes, there
are no interventions for proxy decision-makers. We have developed a
decision support tool which aims to support families making deci-
sions about research participation on behalf of an adult who lacks
capacity to consent.
Methods: The intervention was developed using the MRC guidance
for the development of complex interventions, which recommends a
phased approach using available evidence and theoretical principles.
The intervention was informed by a systematic review, analysis of
existing information provision, qualitative interviews with families
who had acted as proxies, and the development of a theoretical
framework. The intervention was iteratively developed in conjunction
with lay advisors and relevant stakeholders.
Results: Utilising our previous research findings, and applying decision-
support development frameworks, we identified the complex interven-
tion components. We developed a decision-support tool which in-
cludes information about the proxy’s role and the basis for their
decision, and uses values clarification and decision-support methods.
This is supported by a brief training intervention for the researcher/clin-
ician seeking consent. We conducted acceptability testing with a group
of stakeholders which found high levels of acceptability.
Discussion: Ensuring the inclusion of under-represented or vulner-
able groups in randomised trials is a priority area. A novel interven-
tion has been developed to support families making proxy decisions
about research. The decision-support tool is acceptable to users but
requires feasibility testing and establishment of outcome measures
prior to any future evaluation of its effectiveness.
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Introduction: Good research ideas often do not produce the antici-
pated results.[1] It is unknown which intervention development pro-
cesses lead to real world impact on health outcomes as they are
seldom published. Is this a missed opportunity for learning? Could
there be avoidable waste? The UK Medical Research Council and Na-
tional Institute of Health Research funded INDEX study aimed to pro-
duce guidance for researchers on how to develop and report complex
interventions to improve health or health care outcomes.
Methods: Evidence was triangulated from: two systematic reviews, qualita-
tive interviews and e-Delphi studies, guided by two international stake-
holder workshops. Systematic reviews of i) published methodological
approaches to intervention development ii) international primary research
studies reporting intervention development, published in 2015-16, to iden-
tify and categorise practices. In parallel, qualitative interviews with a diverse
sample of developers (clinicians, academics, social scientists) and wider
stakeholders (public representatives, funders, journal editors) were analysed
iteratively, inductively and thematically. Data triangulation generated 85
items for two e-Delphis with i) experts in intervention development, ii)
wider stakeholders, to measure consensus and explore reasons for diver-
gence. All data fed into a logic model and final guidance on intervention
development and reporting.
Results: An overview of the guidance will be presented. Key princi-
ples include: iterative cycles of development with stakeholder input
at each cycle; integrate creativity with scientific methods; be open to
failure, change, and consider unintended consequences; look ahead
to future evaluation and real-world implementation. Novel qualitative
insights include: ways to meld the art and the science of design; the
meanings and drivers of “success” and understanding divergence of
opinion.
Conclusions: The guidance provides a comprehensive tool for consider-
ation when undertaking intervention development. Reporting intervention
development processes will promote transparency so that in future re-
searchers can link early design decisions to trial outcomes.
Reference
1. Chalmers et al, Lancet, 2014: https://doi.org/10.1016/S0140-6736(13)62229-1
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Introduction: Addressing recruitment and retention challenges in tri-
als are important priorities for methodological research, but navigat-
ing this growing literature is difficult and time consuming. In 2016,
ORRCA (www.orrca.org.uk) launched a free, online, searchable, data-
base of recruitment research that is currently being updated with re-
cent publications and extended to include retention research
(ORRCA2). We report the latest results including a mapping exercise
of trial recruitment and retention literature, assessment of the data-
base impact and lessons learnt from conducting an international, col-
laborative, methodology project.
Methods: Search strategies from relevant Cochrane reviews were
tailored to the trial recruitment and retention objectives and to
the databases: MEDLINE(Ovid), WoS, Scopus, CINAHL, PyscINFO,
and the Cochrane Library. An international team of reviewers
were trained and quality assurance approaches introduced. Fol-
lowing abstract screening, full texts were retrieved for potentially
eligible articles. Studies evaluating or reporting recruitment or re-
tention strategies and case reports were included. Eligible articles
are being mapped against an agreed framework of recruitment
or retention domains and categorised by evidence type (e.g. ran-
domised or non-randomised evaluations, studies without
evaluation).
Results: 68,900 abstracts and 6,028 full texts have previously been
reviewed for ORRCA, identifying 3,555 eligible articles. Screening of
an additional 14,465 abstracts for ORRCA and 69,740 abstracts for
ORRCA2 by 31 reviewers from six countries is nearly complete. Pre-
dicted number of articles for full text review are 860 and 3,600
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